Mark Malamood, MD, Director of Benign Esophagology in the Temple Esophageal Disease Program, offered commentary to MedPageToday on research presented at Digestive Disease Week 2026 that found the monoclonal antibody dupilumab (Dupixent) led to significant improvements in esophageal distensibility among patients with eosinophilic esophagitis.
800-TEMPLE-MED
Request Appointment
SEARCH TEMPLE HEALTH